HC Wainwright Reiterates Buy Rating for BioNTech (NASDAQ:BNTX)

HC Wainwright reiterated their buy rating on shares of BioNTech (NASDAQ:BNTX - Free Report) in a report issued on Wednesday morning,Benzinga reports. The firm currently has a $138.00 target price on the stock. HC Wainwright also issued estimates for BioNTech's Q2 2025 earnings at $3.78 EPS, Q3 2025 earnings at ($1.12) EPS, Q1 2026 earnings at ($2.24) EPS, Q2 2026 earnings at ($2.27) EPS and FY2026 earnings at ($4.32) EPS.

A number of other equities analysts have also commented on BNTX. Morgan Stanley reduced their price objective on BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price objective on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. The Goldman Sachs Group assumed coverage on BioNTech in a research note on Thursday, May 29th. They set a "neutral" rating and a $110.00 price target on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and set a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. Finally, Leerink Partners set a $112.00 price target on BioNTech in a research note on Monday, June 2nd. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $137.86.

BioNTech Price Performance

BioNTech stock traded up $0.58 on Wednesday, reaching $106.72. The company's stock had a trading volume of 490,569 shares, compared to its average volume of 941,873. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. The company has a market cap of $25.65 billion, a price-to-earnings ratio of -31.39 and a beta of 1.29. The business's fifty day moving average price is $102.79 and its 200 day moving average price is $107.23. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49.

Hedge Funds Weigh In On BioNTech

Hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its stake in BioNTech by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after buying an additional 150 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of BioNTech by 39.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 187,355 shares of the company's stock worth $21,349,000 after acquiring an additional 53,319 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of BioNTech in the fourth quarter worth about $584,000. GAMMA Investing LLC increased its holdings in shares of BioNTech by 5,710.8% in the first quarter. GAMMA Investing LLC now owns 53,634 shares of the company's stock worth $4,884,000 after acquiring an additional 52,711 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in shares of BioNTech in the fourth quarter worth about $238,000. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.